What is the appropriate IM dosage of lorazepam for catatonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IM Lorazepam Dosing for Catatonia

For catatonia with agitation and pacing, administer lorazepam 2 mg IM initially, which can be repeated every 10-15 minutes if needed, with a typical dosing range of 2-4 mg IM per dose, administered up to three times daily (TID) as clinically indicated. 1

Initial IM Dosing Strategy

  • Start with 2 mg IM lorazepam as the initial dose, which aligns with standard preanesthetic IM dosing (0.05 mg/kg up to maximum 4 mg) 1
  • The IM route is appropriate when IV access is unavailable, though therapeutic levels are reached more slowly than with IV administration 1
  • For catatonia specifically, clinical studies demonstrate that 2 mg IM lorazepam administered once or twice within the first 2 hours achieves an 85.7% complete remission rate 2, 3

TID Dosing Protocol

  • Administer 2-4 mg IM every 8 hours (TID) based on clinical response, with doses repeated every 10-15 minutes during acute episodes if catatonic signs persist 4, 1
  • The maximum single IM dose should not exceed 4 mg per administration 1
  • Total daily doses in catatonia treatment studies have ranged from 3-8 mg/day orally, suggesting that 6-12 mg/day IM (2-4 mg TID) is a reasonable and safe range 5

Critical Monitoring Requirements

  • Continuously monitor oxygen saturation due to increased risk of apnea, particularly when benzodiazepines are combined with other sedatives 6, 7
  • Respiratory support equipment must be immediately available at bedside 6, 4
  • Monitor for hypotension, especially in elderly or frail patients 4, 7
  • Watch for paradoxical agitation, which can occasionally occur 4

Response Assessment and Next Steps

  • Assess response within the first 2 hours - early response to lorazepam predicts final outcome 5, 2
  • If no improvement after 1-2 days of adequate lorazepam dosing (typically 3-6 mg/day for at least 3 days), consider escalation to ECT 5, 8
  • Complete resolution of catatonic symptoms occurs in 32-70% of patients with lorazepam alone, with partial improvement in up to 68.7% 5, 8
  • If lorazepam fails, diazepam IV infusion (10 mg in 500 mL normal saline every 8 hours) can be considered as an alternative benzodiazepine strategy 2, 3

Common Pitfalls to Avoid

  • Do not underdose - inadequate dosing (less than 3 mg/day) reduces response rates significantly 5, 8
  • Do not delay ECT consultation if patient fails to respond after 3-5 days of adequate benzodiazepine trial 5, 8
  • Avoid oral administration during acute catatonic episodes with decreased responsiveness due to aspiration risk 6
  • Do not use flumazenil to reverse sedation, as it will precipitate symptom recurrence 6

Special Population Considerations

  • Elderly patients require dose reduction to 0.05-0.1 mg/kg due to decreased metabolism and higher respiratory depression risk 4
  • Adjust dosing in patients with hepatic or renal impairment, particularly with frequent repeated doses 4, 1
  • No specific dose adjustment needed for single acute doses in renal disease, but exercise caution with repeated dosing 1

References

Guideline

Intramuscular Lorazepam Dosing for Seizure Activity in Elderly Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Catatonic syndrome : treatment response to Lorazepam.

Indian journal of psychiatry, 1999

Guideline

Seizure Management with Lorazepam

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diazepam IM Dosing Equivalent for Catatonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Response rate of lorazepam in catatonia: a developing country's perspective.

Progress in neuro-psychopharmacology & biological psychiatry, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.